# reload+after+2024-01-22 06:45:26.046778
address1§Paul-Ehrlich-Strasse 15
city§Tübingen
zip§72076
country§Germany
phone§49 7071 5397 0
fax§49 7071 5397 900
website§https://www.immatics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
fullTimeEmployees§433
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Harpreet  Singh Ph.D.', 'age': 48, 'title': 'CEO, MD, Member of Management Board & Executive Director', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 902000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Toni  Weinschenk Ph.D.', 'age': 49, 'title': 'Co-Founder & Chief Innovation Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Arnd  Christ MBA', 'age': 57, 'title': 'Chief Financial Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Steffen  Walter Ph.D.', 'age': 46, 'title': 'Chief Operations Officer', 'yearBorn': 1977, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Carsten  Reinhardt M.D., Ph.D.', 'age': 56, 'title': 'Chief Development Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Rainer  Kramer Ph.D.', 'age': 58, 'title': 'Chief Business Officer & Site Head Munich', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Cedrik M. Britten M.D.', 'age': 47, 'title': 'Chief Medical Officer', 'yearBorn': 1976, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Hans-Georg  Rammensee Ph.D.', 'title': 'Co-Founder & Member of the Scientific Advisory Board', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kristijan  Lasic', 'title': 'Director of Accounting', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Emmanuelle  Schuler M.B.A., Ph.D.', 'title': 'VP of Administration & Operations and US Site Head', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.65
priceToSalesTrailing12Months§11.649101
currency§USD
dateShortInterest§1702598400
forwardEps§-1.45
pegRatio§-0.56
exchange§NCM
quoteType§EQUITY
shortName§Immatics N.V.
longName§Immatics N.V.
firstTradeDateEpochUtc§1544625000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§962d0ef0-fe1e-3809-bf51-f3186685ad4f
gmtOffSetMilliseconds§-18000000
targetHighPrice§25.08
targetLowPrice§14.05
targetMeanPrice§19.21
targetMedianPrice§20.06
recommendationMean§1.5
recommendationKey§strong_buy
numberOfAnalystOpinions§7
quickRatio§3.033
grossMargins§-0.49546
ebitdaMargins§-0.93184
trailingPegRatio§None
